{"success":true,"data":{"pressRelease":{"id":"32207","rtpr_id":"nGNE9bYfSV","ticker":"MOLN","exchange":"","all_tickers":["MOLN"],"title":"Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317","author":"Globe Newswire","published_at":"2026-05-12T20:00:00.376Z","article_body":"* Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple\nclinical sites opening and initial clinical data expected in 2026\n\n\n* New data on Radio-DARPins’ amenability to range of therapeutic payloads\nenable isotope-agnostic strategy for expanding pipeline \n\n\n* Strong financial position with cash including short-term time deposits of\nCHF 79 million (approx. USD 100 million), providing runway until late 2027\nZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE\nNEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners\n(https://www.globenewswire.com/Tracker?data=Pb97eXsUjo1ZzhorlH4HwlM0Kdh4WPd4DFBosWdTuec5_Cuul9H4Yn-kgHUSCKhbdFo8_o9KF2sCtugDK-c8AwixARfwTXoxI8WV-h_HJ7A=)\nAG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a\nnovel class of custom-built protein drugs known as DARPin therapeutics\n(“Molecular Partners” or the “Company”), today announced corporate\nhighlights and unaudited financial results for the first quarter of 2026.\n\n\"Molecular Partners had a strong start to 2026, with two clinical studies\ninitiated. Our lead Radio-DARPin program, MP0712 targeting DLL3, is advancing\nin a Phase 1/2a trial, with clinical sites open and initial data anticipated\nthis year. In addition, our new data highlight the ability to interchange\nisotopes on Radio-DARPins, including Lead-212 and Actinium-225, enabling our\nisotope-agnostic strategy in Radio. It is an exciting time for our company,\nand we have a strong financial position supporting the development of our\ngrowing pipeline of candidates,” said Patrick Amstutz, Ph.D., CEO of\nMolecular Partners.\n\nResearch & Development Highlights\n\nMP0712 & Radio-DARPin Pipeline\n\nThe US multicenter Phase 1/2a study of MP0712 has started (ClinicalTrials.gov:\nNCT07278479) and is recruiting. Four clinical sites are now open, with a total\nof nine expected by the end of 2026. Molecular Partners will present\ntrial-in-progress posters on the Phase 1/2a study at the 2026 Annual Meeting\nof the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and 2026\nAmerican Society of Clinical Oncology (ASCO) Annual Meeting and expects to\nshare initial clinical data from this study in 2026.\n\nMP0712 is the Company’s lead Radio-DARPin Therapy (RDT) targeting the\ntumor-associated protein delta-like ligand 3 (DLL3) and carrying the\ntherapeutic payload (212)Pb. MP0712 is being co-developed with Molecular\nPartners’ strategic partner Orano Med, a pioneer in targeted alpha therapy,\nfor the treatment of patients with small cell lung cancer (SCLC) and other\nneuroendocrine cancers. The Phase 1/2a study objectives are to assess safety\nand determine a recommended Phase 2 dose for MP0712. The study contains a\npre-treatment imaging and dosimetry step with (203)Pb-labeled MP0712.\n\nMolecular Partners and the NuMeRI team of Dr. Mike Sathekge presented first\npatient imaging and dosimetry data on MP0712 at the 8th Theranostics World\nCongress (TWC) in January 2026. The data from five evaluable patients with\nvarious DLL3-expressing cancers, including SCLC, urothelial, and other\nneuroendocrine cancers, were generated with MP0712 carrying the diagnostic\nisotope (203)Pb as part of a Named Patient Access Program under the legal\nframework for compassionate care in South Africa. The dosimetry data and the\nimages, which showed specific uptake as well as robust accumulation of MP0712\nin tumor lesions and limited uptake in healthy tissues, as intended, are\nsupportive of the clinical development plans of MP0712 carrying the\ntherapeutic isotope (212)Pb.\n\nThe Company’s second RDT program MP0726 targets mesothelin (MSLN), a tumor\ntarget overexpressed across several cancers with high unmet need, such as\novarian cancer. Molecular Partners has developed Radio-DARPins able to\nselectively bind to membrane-bound MSLN without being impacted by shed MSLN\n– a mechanism which has hampered the development of other MSLN-targeting\ntherapeutics. Molecular Partners intends to advance MP0726 towards\nfirst-in-human imaging within the second half of 2026.\n\nMolecular Partners is evaluating tumor targets in an isotope-agnostic manner\nfor its Radio-DARPin pipeline and expects to nominate a new target in the\nsecond half of the year.\n\nMolecular Partners presented pre-clinical data at the 3(rd) Global\nRadiopharmaceuticals Development Summit (RDS) in March 2026, outlining the\nsuitability of Radio-DARPins to different isotopes. The data showed that the\nCompany’s Radio-DARPin vector design allows interchangeability of alpha\nisotopes, including (212)Pb and (225)Ac, enabling an isotope-agnostic strategy\nto tailor therapeutic candidates to a specific target and disease biology.\n\nIn February 2026, the Company announced it entered into a non-exclusive\ndevelopment agreement with Eckert & Ziegler, a global leader in\nradiopharmaceutical manufacturing. This will expand the potential of\nRadio-DARPins as vectors for precise delivery of therapeutic alpha-emitting\nisotopes to tumors, now including (225)Ac, in addition to (212)Pb through the\nstrategic partnership with Orano Med.\n\nMP0317 (tumor-localized CD40 agonist)\n\nAn investigator-initiated, proof-of-concept Phase 2 study of MP0317 combined\nwith standard-of-care (SoC) for the treatment of patients with advanced\ncholangiocarcinoma has started, with eight sites activated (NCT07036380) and\npatient treatment ongoing. The study is a randomized, multicenter study in\nFrance and aims to recruit 75 patients (with a 2-to-1 design, including 50\npatients in the experimental arm and 25 in the control arm). The objective of\nthe study is to assess the clinical benefit of MP0317 combined with SoC\ncomprising the immunotherapy durvalumab, an anti-PD-L1 checkpoint inhibitor,\nplus gemcitabine-cisplatin-based chemotherapy, compared to SoC alone. MP0317,\na FAP-localized CD40 agonist designed to lead to immune-mediated reshaping of\nthe tumor microenvironment (TME), is hypothesized to improve the 12-month\nprogression-free survival rate of patients compared to those treated with SoC\nonly. The TME is known to play a crucial role in the development of\ncholangiocarcinoma, and of other solid tumor indications, and in treatment\nresistance.\n\nThe Company recently published in Nature Cancer\n(https://www.globenewswire.com/Tracker?data=S5BuDoH88ZmML9sCRbUIcDJUYW8HFNALKRSraZbVu8Eujl5iI1bXeaiQ7B4mdllB055c5Y8lxi45iq5aRs3hGjZdfltEuOXEnzmUkhusgqS1ZtQ4iNVw96PWAtQ6awc8)\n(Steeghs et al. 2026 (e-pub 1 May); DOI: 10.1038/s43018-026-01150-1) the\nresults from the completed Phase 1 dose-escalation study of MP0317 in patients\nwith advanced solid tumors (NCT05098405; 46 patients treated across 9 dose\nlevels). Comprehensive biomarker analyses from this trial confirmed\ntumor-localized CD40 activation and remodeling of the TME by MP0317, with a\nfavorable safety profile. In addition, MP0317’s pharmacokinetic profile is\nsuited for combination treatment settings, including checkpoint inhibitors.\nCD40 is an attractive target for cancer immunotherapy due to its strong\nimmune-stimulatory activity. Molecular Partners believes that MP0317’s\ntumor-localized approach has the potential to deliver superior efficacy with\nfewer side effects compared to systemic CD40 agonists.\n\nMP0533 (multispecific T cell engager)\n\nMP0533 is being evaluated in a Phase 1/2a clinical trial for\nrelapsed/refractory acute myeloid leukemia (AML) and myelodysplastic\nsyndrome/AML (NCT05673057), with the dose escalation part fully recruited (10\ncohorts). Last patients are on treatment, including two patients in remission\nfor over one year who reached minimal residual disease (MRD) negativity.\n\nData presented at the 2025 American Society of Hematology (ASH) Annual Meeting\nshowed an acceptable safety profile for MP0533 monotherapy across all 9\nreported treatment cohorts. The pooled data from these 9 cohorts, comprising\nrelapsed/refractory patients, indicate preliminary clinical activity for\nMP0533 independent of genetic risk profile, in particular in patients with low\nbone marrow blast count at baseline across different treatment cohorts.\n\nInitial data from cohort 10 are in line with cohorts 1-9 findings and will\ncontribute to defining a recommended dose range for MP0533. The results of\nthis study support the exploration of MP0533 in combination with other AML\ntherapies, and Molecular Partners has been approached by several consortia\nexpressing interest in conducting such studies.\n\nMP0533 is a novel tetra-specific T cell-engaging DARPin designed for selective\nand broad killing of AML cells in a mutation-agnostic manner. MP0533’s mode\nof action enables T cell-mediated killing of AML cells – which commonly\nco-express at least two of the three targeted antigens (CD33, CD123, CD70) –\nwhile preserving a therapeutic window that minimizes damage to healthy cells,\nwhich normally express one or none of the targets.\n\nMP0632 and Switch-DARPin Platform (logic-gated immune cell engagers)\n\nMolecular Partners presented new pre-clinical data on its Switch-DARPin T cell\nengager, with MP0632 announced as lead, at the American Association for Cancer\nResearch (AACR) Annual Meeting in April 2026. These data support\nproof-of-concept of the Switch-DARPin design, showing that MP0632 leads to\nregression of established tumors expressing both EpCAM and MSLN, with minimal\nimpact on tumors expressing only one of the antigens, thereby indicating a\nfavorable therapeutic window. In addition, MP0632 allowed for safe use of\npotent CD2 co-stimulation for efficient tumor cell killing with low cytokine\nrelease profile. The data support MP0632’s potential as clinical lead\ncandidate for the treatment of solid cancers expressing MSLN and EpCAM,\nincluding ovarian, endometrial, pancreatic, and other cancers.\n\nMP0632 is a logic-gated Switch-DARPin T-cell engager (TCE), designed to\nachieve conditional tumor-localized immune activation targeting MSLN and\nEpCAM, which are highly co-expressed in ovarian cancer and other solid tumors.\nThe CD3-engaging DARPin is unmasked (“Switched” on) and activates T cells\nonly upon binding to both MSLN and EpCAM. MP0632 is half-life extended through\na Fc domain, which broadens the Company’s capabilities in half-life\nengineering modalities.\n\nCorporate Governance Highlights\n\nAll motions proposed by the Board of Directors at the Annual General Meeting,\nheld in April, were approved by the shareholders of the Company by a wide\nmajority.\n\nThis included the election of Clare Fisher by shareholders to the Board of\nDirectors. Clare Fisher has more than two decades of healthcare experience in\nleadership roles, including corporate and business development, mergers and\nacquisitions, and strategy. She is currently the SVP for Global Business\nDevelopment and M&A at BeOne Medicines, a global oncology company committed to\ndiscovering and developing innovative treatments for cancer patients\nworldwide.\n\nFinancial and Business Outlook\n\nThe Company's cash and cash equivalents and short-term time deposits were CHF\n79 million (approximately USD 100 million) as of March 31, 2026, which, based\non current operating assumptions, will be sufficient to fund its operations\nand capital requirements into late 2027 (previously early 2028) with increased\nR&D investment in an expanding pipeline.\n\nFinancial Calendar\n\n August 25, 2026   Half-year results 2026                            \n October 29, 2026  Interim Management Statement Q3 2026 (unaudited)  \n\nThe latest timing of the above events can be viewed on the investor section\n(https://www.globenewswire.com/Tracker?data=mbrvifnss9tYZnqMT2MY5y3mkogLeO7w_o-aH4Z9pB4XE4O8PyZZccIRQeYRPBhbO9LqH_i8Fq_IbkbqPuHpB5S97wU9ZOt3Cc-WDWdA8ZPi6dw8SSTraC8_2ZzqMAqG) of\nthe website.\n\nAbout DARPin Therapeutics\nDARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of\nprotein drugs based on natural binding proteins, which have been\nclinically-validated across several therapeutic areas and developed through to\nthe registrational stage. The key properties of DARPins – intrinsic\npotential for high affinity and specificity, as well as small size, flexible\narchitecture, and high stability – offer unmatched advantages to drug\ndesign, such as multispecificity, broad target range, and tunable half-life.\nThe Company’s Radio-DARPins enable highly effective and specific delivery of\npotent radioactive payloads to tumor lesions while sparing healthy tissues.\nMolecular Partners’ Switch-DARPins allow conditional, tumor-localized immune\nactivation, which enables increased safety and potency for next-generation\nimmune cell engagers. Powered by twenty years of DARPin leadership, Molecular\nPartners has built an innovative, rapid and cost-effective DARPin drug design\nengine, including proprietary DARPin libraries and platforms, for candidates\nproduced with optimized properties and tailored to therapeutic needs.\n\nAbout Molecular Partners AG \nMolecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech\ncompany pioneering a novel class of protein drugs known as DARPin\ntherapeutics, for medical challenges other treatment modalities cannot readily\naddress. Molecular Partners leverages the key properties of DARPins to design\nand develop differentiated therapeutics for cancer patients, including\ntargeted radiopharmaceuticals and next-generation immune cell engagers. The\nCompany has proprietary programs in various stages of pre-clinical and\nclinical development, as well as programs developed through partnerships with\nleading pharmaceutical companies and academic centers. Molecular Partners,\nfounded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA.\nFor more information, visit www.molecularpartners.com and find us on LinkedIn\nand Twitter / X @MolecularPrtnrs\n\nFor further details, please contact:\nSeth Lewis, EVP Corporate Finance \nConcord, Massachusetts, U.S.\nseth.lewis@molecularpartners.com\nTel: +1 781 420 2361\n\nLaura Jeanbart, PhD, Head of Portfolio Management & Communications \nZurich-Schlieren, Switzerland\nlaura.jeanbart@molecularpartners.com \nTel: +41 44 575 19 35\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward looking statements. Any statements\ncontained in this press release that do not describe historical facts may\nconstitute forward-looking statements as that term is defined in the Private\nSecurities Litigation Reform Act of 1995, as amended, including without\nlimitation: implied and express statements regarding the clinical development\nof Molecular Partners’ current or future product candidates; expectations\nregarding timing for reporting data from ongoing clinical trials or the\ninitiation of future clinical trials; the potential therapeutic and clinical\nbenefits of Molecular Partners’ product candidates and its RDT and\nSwitch-DARPin platforms; the selection and development of future programs;\nMolecular Partners’ collaboration with Orano Med including the benefits and\nresults that may be achieved through the collaboration; and Molecular\nPartners’ expected business and financial outlook, including anticipated\nexpenses and cash utilization for 2026 and its expectation of its current cash\nrunway. These statements may be identified by words such as “aim”,\n\"anticipate\", “expect”, “guidance”, “intend”, “outlook”,\n“plan”, “potential”, “will” and similar expressions, and are based\non Molecular Partners’ current beliefs and expectations. These statements\ninvolve risks and uncertainties that could cause actual results to differ\nmaterially from those reflected in such statements. Some of the key factors\nthat could cause actual results to differ from Molecular Partners’\nexpectations include, but are not limited to, those set forth in under the\nheading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F\nfor the year ended December 31, 2025 and other filings Molecular Partners\nmakes with the SEC from time to time. These documents are available on the\nInvestors page of Molecular Partners’ website at www.molecularpartners.com.\nIn addition, this press release contains information relating to interim data\nas of the relevant data cutoff date, results of which may differ from topline\nresults that may be obtained in the future.\n\nAny forward-looking statements speak only as of the date of this press release\nand are based on information available to Molecular Partners as of the date of\nthis release, and Molecular Partners assumes no obligation to, and does not\nintend to, update any forward-looking statements, whether as a result of new\ninformation, future events or otherwise.","article_body_html":"","raw_payload":{"data":{"id":"nGNE9bYfSV","title":"Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317","author":"Globe Newswire","ticker":"MOLN","created":"2026-05-12T20:00:00.376Z","tickers":["MOLN"],"exchange":"","article_body":"* Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple\nclinical sites opening and initial clinical data expected in 2026\n\n\n* New data on Radio-DARPins’ amenability to range of therapeutic payloads\nenable isotope-agnostic strategy for expanding pipeline \n\n\n* Strong financial position with cash including short-term time deposits of\nCHF 79 million (approx. USD 100 million), providing runway until late 2027\nZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE\nNEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners\n(https://www.globenewswire.com/Tracker?data=Pb97eXsUjo1ZzhorlH4HwlM0Kdh4WPd4DFBosWdTuec5_Cuul9H4Yn-kgHUSCKhbdFo8_o9KF2sCtugDK-c8AwixARfwTXoxI8WV-h_HJ7A=)\nAG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a\nnovel class of custom-built protein drugs known as DARPin therapeutics\n(“Molecular Partners” or the “Company”), today announced corporate\nhighlights and unaudited financial results for the first quarter of 2026.\n\n\"Molecular Partners had a strong start to 2026, with two clinical studies\ninitiated. Our lead Radio-DARPin program, MP0712 targeting DLL3, is advancing\nin a Phase 1/2a trial, with clinical sites open and initial data anticipated\nthis year. In addition, our new data highlight the ability to interchange\nisotopes on Radio-DARPins, including Lead-212 and Actinium-225, enabling our\nisotope-agnostic strategy in Radio. It is an exciting time for our company,\nand we have a strong financial position supporting the development of our\ngrowing pipeline of candidates,” said Patrick Amstutz, Ph.D., CEO of\nMolecular Partners.\n\nResearch & Development Highlights\n\nMP0712 & Radio-DARPin Pipeline\n\nThe US multicenter Phase 1/2a study of MP0712 has started (ClinicalTrials.gov:\nNCT07278479) and is recruiting. Four clinical sites are now open, with a total\nof nine expected by the end of 2026. Molecular Partners will present\ntrial-in-progress posters on the Phase 1/2a study at the 2026 Annual Meeting\nof the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and 2026\nAmerican Society of Clinical Oncology (ASCO) Annual Meeting and expects to\nshare initial clinical data from this study in 2026.\n\nMP0712 is the Company’s lead Radio-DARPin Therapy (RDT) targeting the\ntumor-associated protein delta-like ligand 3 (DLL3) and carrying the\ntherapeutic payload (212)Pb. MP0712 is being co-developed with Molecular\nPartners’ strategic partner Orano Med, a pioneer in targeted alpha therapy,\nfor the treatment of patients with small cell lung cancer (SCLC) and other\nneuroendocrine cancers. The Phase 1/2a study objectives are to assess safety\nand determine a recommended Phase 2 dose for MP0712. The study contains a\npre-treatment imaging and dosimetry step with (203)Pb-labeled MP0712.\n\nMolecular Partners and the NuMeRI team of Dr. Mike Sathekge presented first\npatient imaging and dosimetry data on MP0712 at the 8th Theranostics World\nCongress (TWC) in January 2026. The data from five evaluable patients with\nvarious DLL3-expressing cancers, including SCLC, urothelial, and other\nneuroendocrine cancers, were generated with MP0712 carrying the diagnostic\nisotope (203)Pb as part of a Named Patient Access Program under the legal\nframework for compassionate care in South Africa. The dosimetry data and the\nimages, which showed specific uptake as well as robust accumulation of MP0712\nin tumor lesions and limited uptake in healthy tissues, as intended, are\nsupportive of the clinical development plans of MP0712 carrying the\ntherapeutic isotope (212)Pb.\n\nThe Company’s second RDT program MP0726 targets mesothelin (MSLN), a tumor\ntarget overexpressed across several cancers with high unmet need, such as\novarian cancer. Molecular Partners has developed Radio-DARPins able to\nselectively bind to membrane-bound MSLN without being impacted by shed MSLN\n– a mechanism which has hampered the development of other MSLN-targeting\ntherapeutics. Molecular Partners intends to advance MP0726 towards\nfirst-in-human imaging within the second half of 2026.\n\nMolecular Partners is evaluating tumor targets in an isotope-agnostic manner\nfor its Radio-DARPin pipeline and expects to nominate a new target in the\nsecond half of the year.\n\nMolecular Partners presented pre-clinical data at the 3(rd) Global\nRadiopharmaceuticals Development Summit (RDS) in March 2026, outlining the\nsuitability of Radio-DARPins to different isotopes. The data showed that the\nCompany’s Radio-DARPin vector design allows interchangeability of alpha\nisotopes, including (212)Pb and (225)Ac, enabling an isotope-agnostic strategy\nto tailor therapeutic candidates to a specific target and disease biology.\n\nIn February 2026, the Company announced it entered into a non-exclusive\ndevelopment agreement with Eckert & Ziegler, a global leader in\nradiopharmaceutical manufacturing. This will expand the potential of\nRadio-DARPins as vectors for precise delivery of therapeutic alpha-emitting\nisotopes to tumors, now including (225)Ac, in addition to (212)Pb through the\nstrategic partnership with Orano Med.\n\nMP0317 (tumor-localized CD40 agonist)\n\nAn investigator-initiated, proof-of-concept Phase 2 study of MP0317 combined\nwith standard-of-care (SoC) for the treatment of patients with advanced\ncholangiocarcinoma has started, with eight sites activated (NCT07036380) and\npatient treatment ongoing. The study is a randomized, multicenter study in\nFrance and aims to recruit 75 patients (with a 2-to-1 design, including 50\npatients in the experimental arm and 25 in the control arm). The objective of\nthe study is to assess the clinical benefit of MP0317 combined with SoC\ncomprising the immunotherapy durvalumab, an anti-PD-L1 checkpoint inhibitor,\nplus gemcitabine-cisplatin-based chemotherapy, compared to SoC alone. MP0317,\na FAP-localized CD40 agonist designed to lead to immune-mediated reshaping of\nthe tumor microenvironment (TME), is hypothesized to improve the 12-month\nprogression-free survival rate of patients compared to those treated with SoC\nonly. The TME is known to play a crucial role in the development of\ncholangiocarcinoma, and of other solid tumor indications, and in treatment\nresistance.\n\nThe Company recently published in Nature Cancer\n(https://www.globenewswire.com/Tracker?data=S5BuDoH88ZmML9sCRbUIcDJUYW8HFNALKRSraZbVu8Eujl5iI1bXeaiQ7B4mdllB055c5Y8lxi45iq5aRs3hGjZdfltEuOXEnzmUkhusgqS1ZtQ4iNVw96PWAtQ6awc8)\n(Steeghs et al. 2026 (e-pub 1 May); DOI: 10.1038/s43018-026-01150-1) the\nresults from the completed Phase 1 dose-escalation study of MP0317 in patients\nwith advanced solid tumors (NCT05098405; 46 patients treated across 9 dose\nlevels). Comprehensive biomarker analyses from this trial confirmed\ntumor-localized CD40 activation and remodeling of the TME by MP0317, with a\nfavorable safety profile. In addition, MP0317’s pharmacokinetic profile is\nsuited for combination treatment settings, including checkpoint inhibitors.\nCD40 is an attractive target for cancer immunotherapy due to its strong\nimmune-stimulatory activity. Molecular Partners believes that MP0317’s\ntumor-localized approach has the potential to deliver superior efficacy with\nfewer side effects compared to systemic CD40 agonists.\n\nMP0533 (multispecific T cell engager)\n\nMP0533 is being evaluated in a Phase 1/2a clinical trial for\nrelapsed/refractory acute myeloid leukemia (AML) and myelodysplastic\nsyndrome/AML (NCT05673057), with the dose escalation part fully recruited (10\ncohorts). Last patients are on treatment, including two patients in remission\nfor over one year who reached minimal residual disease (MRD) negativity.\n\nData presented at the 2025 American Society of Hematology (ASH) Annual Meeting\nshowed an acceptable safety profile for MP0533 monotherapy across all 9\nreported treatment cohorts. The pooled data from these 9 cohorts, comprising\nrelapsed/refractory patients, indicate preliminary clinical activity for\nMP0533 independent of genetic risk profile, in particular in patients with low\nbone marrow blast count at baseline across different treatment cohorts.\n\nInitial data from cohort 10 are in line with cohorts 1-9 findings and will\ncontribute to defining a recommended dose range for MP0533. The results of\nthis study support the exploration of MP0533 in combination with other AML\ntherapies, and Molecular Partners has been approached by several consortia\nexpressing interest in conducting such studies.\n\nMP0533 is a novel tetra-specific T cell-engaging DARPin designed for selective\nand broad killing of AML cells in a mutation-agnostic manner. MP0533’s mode\nof action enables T cell-mediated killing of AML cells – which commonly\nco-express at least two of the three targeted antigens (CD33, CD123, CD70) –\nwhile preserving a therapeutic window that minimizes damage to healthy cells,\nwhich normally express one or none of the targets.\n\nMP0632 and Switch-DARPin Platform (logic-gated immune cell engagers)\n\nMolecular Partners presented new pre-clinical data on its Switch-DARPin T cell\nengager, with MP0632 announced as lead, at the American Association for Cancer\nResearch (AACR) Annual Meeting in April 2026. These data support\nproof-of-concept of the Switch-DARPin design, showing that MP0632 leads to\nregression of established tumors expressing both EpCAM and MSLN, with minimal\nimpact on tumors expressing only one of the antigens, thereby indicating a\nfavorable therapeutic window. In addition, MP0632 allowed for safe use of\npotent CD2 co-stimulation for efficient tumor cell killing with low cytokine\nrelease profile. The data support MP0632’s potential as clinical lead\ncandidate for the treatment of solid cancers expressing MSLN and EpCAM,\nincluding ovarian, endometrial, pancreatic, and other cancers.\n\nMP0632 is a logic-gated Switch-DARPin T-cell engager (TCE), designed to\nachieve conditional tumor-localized immune activation targeting MSLN and\nEpCAM, which are highly co-expressed in ovarian cancer and other solid tumors.\nThe CD3-engaging DARPin is unmasked (“Switched” on) and activates T cells\nonly upon binding to both MSLN and EpCAM. MP0632 is half-life extended through\na Fc domain, which broadens the Company’s capabilities in half-life\nengineering modalities.\n\nCorporate Governance Highlights\n\nAll motions proposed by the Board of Directors at the Annual General Meeting,\nheld in April, were approved by the shareholders of the Company by a wide\nmajority.\n\nThis included the election of Clare Fisher by shareholders to the Board of\nDirectors. Clare Fisher has more than two decades of healthcare experience in\nleadership roles, including corporate and business development, mergers and\nacquisitions, and strategy. She is currently the SVP for Global Business\nDevelopment and M&A at BeOne Medicines, a global oncology company committed to\ndiscovering and developing innovative treatments for cancer patients\nworldwide.\n\nFinancial and Business Outlook\n\nThe Company's cash and cash equivalents and short-term time deposits were CHF\n79 million (approximately USD 100 million) as of March 31, 2026, which, based\non current operating assumptions, will be sufficient to fund its operations\nand capital requirements into late 2027 (previously early 2028) with increased\nR&D investment in an expanding pipeline.\n\nFinancial Calendar\n\n August 25, 2026   Half-year results 2026                            \n October 29, 2026  Interim Management Statement Q3 2026 (unaudited)  \n\nThe latest timing of the above events can be viewed on the investor section\n(https://www.globenewswire.com/Tracker?data=mbrvifnss9tYZnqMT2MY5y3mkogLeO7w_o-aH4Z9pB4XE4O8PyZZccIRQeYRPBhbO9LqH_i8Fq_IbkbqPuHpB5S97wU9ZOt3Cc-WDWdA8ZPi6dw8SSTraC8_2ZzqMAqG) of\nthe website.\n\nAbout DARPin Therapeutics\nDARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of\nprotein drugs based on natural binding proteins, which have been\nclinically-validated across several therapeutic areas and developed through to\nthe registrational stage. The key properties of DARPins – intrinsic\npotential for high affinity and specificity, as well as small size, flexible\narchitecture, and high stability – offer unmatched advantages to drug\ndesign, such as multispecificity, broad target range, and tunable half-life.\nThe Company’s Radio-DARPins enable highly effective and specific delivery of\npotent radioactive payloads to tumor lesions while sparing healthy tissues.\nMolecular Partners’ Switch-DARPins allow conditional, tumor-localized immune\nactivation, which enables increased safety and potency for next-generation\nimmune cell engagers. Powered by twenty years of DARPin leadership, Molecular\nPartners has built an innovative, rapid and cost-effective DARPin drug design\nengine, including proprietary DARPin libraries and platforms, for candidates\nproduced with optimized properties and tailored to therapeutic needs.\n\nAbout Molecular Partners AG \nMolecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech\ncompany pioneering a novel class of protein drugs known as DARPin\ntherapeutics, for medical challenges other treatment modalities cannot readily\naddress. Molecular Partners leverages the key properties of DARPins to design\nand develop differentiated therapeutics for cancer patients, including\ntargeted radiopharmaceuticals and next-generation immune cell engagers. The\nCompany has proprietary programs in various stages of pre-clinical and\nclinical development, as well as programs developed through partnerships with\nleading pharmaceutical companies and academic centers. Molecular Partners,\nfounded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA.\nFor more information, visit www.molecularpartners.com and find us on LinkedIn\nand Twitter / X @MolecularPrtnrs\n\nFor further details, please contact:\nSeth Lewis, EVP Corporate Finance \nConcord, Massachusetts, U.S.\nseth.lewis@molecularpartners.com\nTel: +1 781 420 2361\n\nLaura Jeanbart, PhD, Head of Portfolio Management & Communications \nZurich-Schlieren, Switzerland\nlaura.jeanbart@molecularpartners.com \nTel: +41 44 575 19 35\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward looking statements. Any statements\ncontained in this press release that do not describe historical facts may\nconstitute forward-looking statements as that term is defined in the Private\nSecurities Litigation Reform Act of 1995, as amended, including without\nlimitation: implied and express statements regarding the clinical development\nof Molecular Partners’ current or future product candidates; expectations\nregarding timing for reporting data from ongoing clinical trials or the\ninitiation of future clinical trials; the potential therapeutic and clinical\nbenefits of Molecular Partners’ product candidates and its RDT and\nSwitch-DARPin platforms; the selection and development of future programs;\nMolecular Partners’ collaboration with Orano Med including the benefits and\nresults that may be achieved through the collaboration; and Molecular\nPartners’ expected business and financial outlook, including anticipated\nexpenses and cash utilization for 2026 and its expectation of its current cash\nrunway. These statements may be identified by words such as “aim”,\n\"anticipate\", “expect”, “guidance”, “intend”, “outlook”,\n“plan”, “potential”, “will” and similar expressions, and are based\non Molecular Partners’ current beliefs and expectations. These statements\ninvolve risks and uncertainties that could cause actual results to differ\nmaterially from those reflected in such statements. Some of the key factors\nthat could cause actual results to differ from Molecular Partners’\nexpectations include, but are not limited to, those set forth in under the\nheading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F\nfor the year ended December 31, 2025 and other filings Molecular Partners\nmakes with the SEC from time to time. These documents are available on the\nInvestors page of Molecular Partners’ website at www.molecularpartners.com.\nIn addition, this press release contains information relating to interim data\nas of the relevant data cutoff date, results of which may differ from topline\nresults that may be obtained in the future.\n\nAny forward-looking statements speak only as of the date of this press release\nand are based on information available to Molecular Partners as of the date of\nthis release, and Molecular Partners assumes no obligation to, and does not\nintend to, update any forward-looking statements, whether as a result of new\ninformation, future events or otherwise."},"type":"article","timestamp":"2026-05-12T20:00:00.463101753Z","server_sent_at_ms":1778616000463},"received_at":"2026-05-12T20:00:01.022Z","source_url":null},"analysis":{"id":"23317","press_release_id":"32207","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Molecular Partners has initiated clinical studies for its lead Radio-DARPin MP0712 and MP0317, with multiple sites now open and initial data expected in 2026.\n\nThe company presented new data at the 8th Theranostics World Congress, showing specific uptake and robust accumulation of MP0712 in tumor lesions, supporting its clinical development plans.\n\nMolecular Partners entered into a non-exclusive development agreement with Eckert & Ziegler, expanding the potential of Radio-DARPins to include (225)Ac as a therapeutic isotope.\n\nThe company has a strong financial position with cash and short-term time deposits totaling CHF 79 million (approximately USD 100 million), providing runway until late 2027.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Multiple clinical advancements and strong financial position support ongoing development."},"keyFigures":{"customDimensions":{"runway":"until late 2027","cash_and_short_term_deposits":"CHF 79 million (approx. USD 100 million)"}},"quotedText":"Molecular Partners had a strong start to 2026, with two clinical studies initiated. Our lead Radio-DARPin program, MP0712 targeting DLL3, is advancing in a Phase 1/2a trial, with clinical sites open and initial data anticipated this year.","namedEntities":{"people":[{"name":"Patrick Amstutz, Ph.D.","role":"CEO"},{"name":"Clare Fisher","role":"SVP for Global Business Development and M&A at BeOne Medicines"},{"name":"Seth Lewis","role":"EVP Corporate Finance"},{"name":"Laura Jeanbart, PhD","role":"Head of Portfolio Management & Communications"},{"name":"Dr. Mike Sathekge","role":"NuMeRI team"}],"products":["MP0712","MP0317","MP0533","MP0632","DARPin therapeutics","Radio-DARPins","Switch-DARPins"],"companies":[{"name":"Molecular Partners AG","ticker":"MOLN"},{"name":"Orano Med","relationship":"strategic partner"},{"name":"Eckert & Ziegler","relationship":"development partner"},{"name":"BeOne Medicines","relationship":"employer of Clare Fisher"}],"dollarAmounts":[{"amount":"CHF 79 million","context":"cash and short-term time deposits as of March 31, 2026"},{"amount":"USD 100 million","context":"approximate value of cash and short-term time deposits as of March 31, 2026"}]},"materialImpact":{"score":4,"reasoning":"The company has initiated multiple clinical studies, presented positive pre-clinical data, and entered into a development agreement with a leading radiopharmaceutical manufacturer. Strong financial position supports ongoing development."},"tickerRelevance":{"others":[],"primary":"MOLN"},"globalImportance":45,"audienceRelevance":60,"eventTypeSecondary":["clinical_trial","partnership"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"multiple clinical studies and partnerships","issuerAuthored":true,"financialStrength":"strong cash position"}},"event_type":"operations_update","event_type_secondary":["clinical_trial","partnership"],"sentiment":"bullish","material_impact_score":4,"narrative":"Molecular Partners has initiated clinical studies for its lead Radio-DARPin MP0712 and MP0317, with multiple sites now open and initial data expected in 2026.\n\nThe company presented new data at the 8th Theranostics World Congress, showing specific uptake and robust accumulation of MP0712 in tumor lesions, supporting its clinical development plans.\n\nMolecular Partners entered into a non-exclusive development agreement with Eckert & Ziegler, expanding the potential of Radio-DARPins to include (225)Ac as a therapeutic isotope.\n\nThe company has a strong financial position with cash and short-term time deposits totaling CHF 79 million (approximately USD 100 million), providing runway until late 2027.","key_figures":{"customDimensions":{"runway":"until late 2027","cash_and_short_term_deposits":"CHF 79 million (approx. USD 100 million)"}},"named_entities":{"people":[{"name":"Patrick Amstutz, Ph.D.","role":"CEO"},{"name":"Clare Fisher","role":"SVP for Global Business Development and M&A at BeOne Medicines"},{"name":"Seth Lewis","role":"EVP Corporate Finance"},{"name":"Laura Jeanbart, PhD","role":"Head of Portfolio Management & Communications"},{"name":"Dr. Mike Sathekge","role":"NuMeRI team"}],"products":["MP0712","MP0317","MP0533","MP0632","DARPin therapeutics","Radio-DARPins","Switch-DARPins"],"companies":[{"name":"Molecular Partners AG","ticker":"MOLN"},{"name":"Orano Med","relationship":"strategic partner"},{"name":"Eckert & Ziegler","relationship":"development partner"},{"name":"BeOne Medicines","relationship":"employer of Clare Fisher"}],"dollarAmounts":[{"amount":"CHF 79 million","context":"cash and short-term time deposits as of March 31, 2026"},{"amount":"USD 100 million","context":"approximate value of cash and short-term time deposits as of March 31, 2026"}]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a68c0d5c02b24190","schema_hash":"sha256:4b22e0a142e5d4b1","created_at":"2026-05-12T20:02:08.462Z","global_importance":45,"audience_relevance":60,"importance_components":{"tickerTier":"mid-cap","eventGravity":"multiple clinical studies and partnerships","issuerAuthored":true,"financialStrength":"strong cash position"}},"durationMs":49997,"modelName":"george-droid-qwen-72b"}}